AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 161 min read$RVTY

Revvity (NYSE: RVTY) executive plans $1M stock sale

Revvity (NYSE: RVTY) officer Tajinder S. Vohra filed a Rule 144 notice to sell up to 7,330 shares, valued at approximately $1.03 million. The shares stem from restricted stock vesting awards. As of September 16, 2026, Revvity had 111,586,401 common shares outstanding.

Original reporting
stocktitan.net
Published Sep 16, 2026, 1:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 2:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RVTY
Neutral
medium confidence
Mentioned
$RVTY
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RVTYNeutralLow
01

Why it matters

The filing informs investors of insider liquidity, offering a data point for monitoring insider sentiment.

02

Market read

Provides a modest update on insider activity; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or earnings that may influence the insider's decision.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; a $1M sale is routine but provides transparency.

Company-level read

Ticker impact

$RVTYNeutralMedium confidence
Context

Officer Tajinder S. Vohra filed a Form 4 to sell 7,330 shares (~$1.03M) of Revvity (RV​TY).

Expected impact

Potential marginal dip in RVTY price, unlikely to move beyond a few cents.

Evidence & confidence

The sale represents a small fraction of total shares and is typical insider liquidity; market impact is limited.

Market effects

Sector

No significant effect on the life sciences sector.

Regional

Limited to Revvity shareholders; no broader regional impact.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The insider sale could be interpreted as a lack of confidence, suggesting a short opportunity.

Key entities

  • Officer
    Tajinder S. Vohra

    Officer of Revvity filing the sale.

  • Company
    Revvity, Inc.

    Life sciences company listed on NYSE under RVTY.

Read at source← All news

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min